| Names | |
|---|---|
| Preferred IUPAC name | Emulsion |
| Other names | Fat Emulsion Lipid Emulsion Intravenous Lipid Emulsion IV Fat Emulsion |
| Pronunciation | /fæt ɪˈmʌl.ʃən ɪnˈdʒek.ʃən/ |
| Identifiers | |
| CAS Number | 8049-98-7 |
| Beilstein Reference | 4-118-09 |
| ChEBI | CHEBI:53422 |
| ChEMBL | CHEMBL1201580 |
| ChemSpider | 23319126 |
| DrugBank | DB09423 |
| ECHA InfoCard | 06ea276a-9a69-4337-8e19-32b4d750f348 |
| EC Number | 220414 |
| Gmelin Reference | Gmelin Reference: 2083847 |
| KEGG | D01746 |
| MeSH | D000081122 |
| PubChem CID | 34463 |
| RTECS number | VX8060000 |
| UNII | C1F8875B92 |
| UN number | UN1856 |
| CompTox Dashboard (EPA) | DTXSID70173676 |
| Properties | |
| Chemical formula | C18H34O2 |
| Appearance | Milky white or almost white homogeneous liquid |
| Odor | Milky white or almost white |
| Density | 0.98 g/mL |
| Solubility in water | Insoluble |
| log P | 3.98 |
| Acidity (pKa) | Acidity (pKa): "7.5–8.5 |
| Magnetic susceptibility (χ) | Magnetic susceptibility (χ): -7.2 × 10⁻⁶ |
| Refractive index (nD) | 1.410 to 1.420 |
| Viscosity | 12-18 mPa·s |
| Dipole moment | '0 D' |
| Pharmacology | |
| ATC code | B05BA02 |
| Hazards | |
| Main hazards | Main hazards: May cause allergic reactions; risk of fat overload syndrome; infection due to intravenous use; risk of hyperlipidemia; potential for embolism if administered improperly. |
| GHS labelling | Not classified as hazardous according to GHS |
| Pictograms | Keep out of reach of children", "Do not freeze", "Protect from light", "For intravenous use only |
| Signal word | Warning |
| Hazard statements | No hazard statement |
| Precautionary statements | Precautionary statements: Use with caution in patients with disorders of lipid metabolism, severe liver disease, or fat overload syndrome. Monitor liver function, serum triglycerides, and signs of fat embolism. Discontinue if adverse reactions occur. |
| NFPA 704 (fire diamond) | 0-1-0 |
| LD50 (median dose) | LD50 (median dose): 44.9 g/kg (mouse, intravenous) |
| NIOSH | CL-207 |
| REL (Recommended) | 2.0–2.5 g/kg BW/d |
| Related compounds | |
| Related compounds | Fish oil emulsion Soybean oil emulsion Medium-chain triglyceride emulsion Olive oil emulsion Lipid injectable emulsion |
| Product Identification | Description & Manufacturer's Commentary |
|---|---|
| Product Name | Fat Emulsion Injection |
| IUPAC Name | Not applicable for mixture-based pharmaceutical emulsions. Major constituents can be listed individually, such as Soybean Oil (IUPAC: (Z,Z,Z)-9,12,15-octadecatrienoic acid triglyceride), Medium-chain triglycerides. Actual emulsion contains mixture of triglycerides, phospholipids, and water for injection. |
| Chemical Formula | Mixture; primary ingredient: C57H104O6 for Triglycerides of Oleic Acid, but presence of linoleic, linolenic acids, and MCT varies by supplier and application. Formula of complete emulsion not representable by single chemical structure due to heterogeneity. |
| Synonyms & Trade Names | Fat Emulsion for Injection, Intravenous Lipid Emulsion, IV Fat Emulsion, Intralipid, Liposyn, Lipofundin. Regional pharmacopeia or regulatory filings standardize naming per local requirements and composition. |
| HS Code & Customs Classification | HS Code: 3004.50 (Medicaments containing vitamins or other products, for human use, not elsewhere specified or included, put up in measured doses or for retail sale). Classification adapts to finished dosage form and regional regulations, as bulk emulsion and final IV solutions may fall under distinct subcodes depending on excipient profiles and packaging state. |
Fat emulsion injections require sourcing of refined triglyceride oils (commonly soybean or fish oil, or a defined blend), pharmaceutical-grade emulsifiers (egg phospholipids or synthetic alternatives), and water for injection. The triglyceride and phospholipid profiles are monitored for fatty acid composition, oxidation levels, trace metals, and residual solvent presence.
Grade selection hinges on emulsion stability, clarity, droplet size distribution, and microbial load. Customer specifications can dictate source, composition (including MCT/LCT ratios), and allergen handling practices. Minor excipients such as glycerol define osmolarity and colloidal stability.
Industrial-scale production involves high-pressure homogenization to ensure submicron droplet size, followed by sterile filtration and aseptic packaging. Process parameters rely on validated procedures for emulsion formation, particle size reduction, and prevention of phase separation. Key process controls include continuous monitoring of temperature, pH, lipid oxidation, peroxide values, and microbial burden. Manufacturing line design is tailored for full CIP/SIP capability due to high sensitivity to pyrogens and bioburden.
Batch consistency is assured by defining critical quality attributes such as mean droplet diameter (often less than 500 nm per pharmacopeia standards), zeta potential, and osmolality. Deviations in raw material profile, mixing energy, or sterilization conditions create batch variability in droplet size and risk destabilization.
Release specifications may reference pharmacopeia standards (USP, Ph. Eur., JP) regarding particle size, sterility, endotoxin content, and chemical purity. The packaging format—ampoule, infusion bag, or bulk tank—dictates whether customs classification treats the material as an active pharmaceutical ingredient or as a medicinal product. Labeling and transport reflect the finished form and target market regulatory requirements.
Fat emulsion injection appears as a milky, opalescent liquid, with form and viscosity changing based on the type and concentration of oil phase, emulsifier blend, and intended clinical use. Standard grades provide an odorless or faintly oily scent. No significant melting or boiling points apply, as these are multiphase emulsions rather than simple substances.
Formulation viscosity and opacity change with oil droplet size, total lipid concentration, and the presence of additives for isotonicity or pH stabilization. High-concentration grades may show increased density and reduced fluidity, directly affecting intravenous flow and filtration suitability.
Stability for fat emulsion injections rides on the emulsion’s ability to resist coalescence, phase separation, or oxidation. Olive, soybean, or fish oil components demand antioxidant stabilization and proper oxygen exclusion during manufacture and storage. Certain clinical additives or drug admixtures can also impact emulsion stability or accelerate degradation reactions, notably with electrolytes and divalent cations.
These emulsions are not true solutions—oil droplets remain suspended via surfactant-mediated interfaces, typically with phospholipid emulsifiers. Proper mixing and dilution should maintain emulsion structure, requiring equipment designed to prevent shear-induced breakdown or air introduction.
| Parameter | Typical Value/Range | Comment |
|---|---|---|
| Droplet Size Distribution | Grade/route dependent | Clinically critical; sub-visible particle size limited by pharmacopoeial requirements and risk of embolism |
| Osmolality | Application-specific | Tailored for intravenous compatibility |
| pH | Defined for stability | Stabilized for lipid and active ingredient compatibility |
Detailed specifications are product-grade driven and subject to adjustment based on targeted patient population, lipid source, and local regulatory standards.
Key impurities arise from raw oil processing, residual solvent traces, and degradation products (hydroperoxides, aldehydes, free fatty acids). Control of pro-oxidant trace metals and bacterial endotoxins remains essential. Limits vary by regulatory region and grade, and internal release standards reflect both pharmacopoeial and customer requirements for parenteral safety.
Routine testing uses light obscuration for droplet sizing, titration methods for peroxide value, and validated chemical methods for phospholipid and triglyceride content. Sterility and pyrogenicity are evaluated by compendial methods outlined in global pharmacopeia.
Selection of oil source functions as a primary control—refined, pharmaceutical-grade vegetable or fish oils form the main lipid phase, chosen for compositional uniformity, low impurity burden, and traceable origin. Emulsifiers must be injectable-grade, often lecithin or synthetic phospholipids, screened for allergenic components and residual solvents.
The process relies on high-shear mechanical dispersion to form a stable oil-in-water emulsion, supported by subsequent thermal sterilization. The reaction mechanisms center on surfactant adsorption at oil–water interfaces and lipid phase dispersion—no covalent chemistry occurs during primary emulsion formation.
Process parameters include temperature control, shear force, homogenization cycles, and oxygen management to prevent emulsion breakdown or lipid oxidation. Inline filtration removes particulate matter above defined particle sizes. In-process sampling monitors pH, droplet size, and sterility pre-filling. Excessive shear can destabilize the emulsion, split oil droplets, or release bound impurities.
Each batch release draws on specifications for critical quality attributes: particle size, osmolality, pH, endotoxin levels, sterility. Release criteria apply both internal standards and those established by pharmacopeial monographs for intravenous lipid emulsions. Any deviation during manufacture or out-of-spec test results prompt batch rejection or reprocessing decisions.
The core emulsification step does not involve significant chemical transformation—chemical reactions concern lipid autoxidation, hydrolysis, and rarely, interaction with metallic container surfaces. Formulation changes, like antioxidant addition or emulsifier substitution, modify reactivity and shelf stability.
Process controls depend on limiting exposure to heat, oxygen, and catalytic surfaces. Some grades incorporate nitrogen blanketing or dark processing to curb oxidation. Antioxidant levels, pH, and ionic content require continuous monitoring; process temperatures are selected to balance microbiological safety with least emulsion destabilization.
Process variations produce specialty emulsions targeting pediatric, neonatal, or nutrition-intensive indications. These derive from modification of oil blends, inclusion of medium-chain triglycerides, or lipid-soluble vitamins.
Fat emulsion injections require avoidance of direct light, excessive heat, and oxygen ingress. Typical storage involves cool, dark places—temperature limits follow product-grade-specific recommendations, mainly to prevent phase separation or hydrolysis. High humidity encourages container corrosion or microbial ingress if primary seal integrity is lost.
Standard containers include glass vials or multilayer plastic bags designed for intravenous use. Migration of plasticizers or leachable substances is controlled through supplier selection and validation trials. Not all grades exhibit compatibility with every class of container.
Actual shelf life varies by fat source and antioxidant system. Degradation typically registers as visible creaming, odor formation, or pH drift. Discard on detection of phase separation, unusual odor, or container swelling.
Parenteral lipid emulsions typically remain unclassified for physical hazards but may have human health hazard warnings per regional requirements.
Industrial exposure routes are limited during closed system manufacture. Accidental skin or inhalation exposure to bulk emulsifier or raw oil can cause local irritation. Injection into animals in toxicology tests mainly causes fat overloading or embolism with excess dose or unsuitable administration.
Acute toxicity depends on dose, route, and patient status. Use in clinical settings is by physician prescription; unapproved or improper administration risks serious adverse effects. Exact LD50 values and chronic toxicity endpoints are referenced from regulatory submissions and pharmacopoeial documentation.
Operator handling risk is minimized through automated filling lines and contained systems. Use proper ventilation, eye/skin protection for bulk raw material transfer or equipment cleaning. Spillage of emulsion residues prompts immediate cleaning to prevent microbial growth or slip hazards.
Production of fat emulsion injection requires established facilities with validated sterile line technology. Output capacity closely tracks with line scheduling efficiency, availability of pharmaceutical-grade triglycerides, and access to refined emulsifying agents. Annual supply volume varies based on recurring orders from hospitals and revised forecasts from institutional buyers. Batch output and site allocation link directly to GMP-certified line availability and regulatory inspection timelines.
Standard lead times depend on current manufacturing schedules and raw material inventory. Contract manufacturing for new customers often entails extended qualification periods and sample batch release testing. Routine orders typically rotate on prearranged production slots, supporting stable lead times. MOQs fluctuate based on specific grade and packaging requirements; clinical grades require higher compliance checks and may set higher MOQs, especially for export-sensitive regions.
Packaging is defined by grade, with main options including Type I glass vials or high barrier polypropylene bags. Volume, closure type, and shipping conditioning depend on route-to-market, end-use (hospital vs. home care), and regional shipping regulations. Packaging lines are validated for sterility and regulatory compliance, and any custom packaging must pass compatibility and extractables/leachables studies.
Shipments prioritize cold chain integrity; logistics routines adhere to GDP-compliant protocols. Payment terms may include sight LC or 30–60 day credit, subject to customer financial review. Export destinations with more frequent inspections may generate expanded release documents, which can affect overall lead times.
Raw material costs mainly depend on pharmaceutical-grade oils (typically soybean or MCT), surfactants, and sterile water. Triglyceride prices fluctuate due to agricultural yield variations, extraction process costs, and climate impact on oilseed crops. Surfactant prices respond to global petrochemical feedstock pricing. Supplier selection and multi-batch lot testing impact total batch cost, especially during supply chain disruptions or sudden regulatory changes upstream.
Grade distinction defines cost: injectable grades require intensive purification, advanced microbial filtration, and validated aseptic processing. Price splits align with sterility assurance levels, impurity profile, and released lot documentation. Higher price tiers reflect comprehensive traceability and full pharmacopoeial compliance.
Grade-specific pricing originates from the number and rigor of purification and sterilization steps, level of in-process control, and the stringency of release tests. Purity requirements for parenteral administration increase both raw material cost and in-process testing frequency. Packaging certification requirements, such as DMF-supported containers or secondary anticounterfeit features, impact packaging material costs and line setup complexity.
Global demand sees cyclical fluctuations, driven by hospital purchasing contracts and national health insurance reimbursement policies. Supply-side constraints appear during agricultural yield shortages, export restrictions, or introduction of new pharmacopoeial monographs. Structural imbalance often appears regionally, especially during periods of regulatory realignment or unforeseen public health demand spikes.
US and EU sourcing rely on validated multi-supplier networks, leveraging robust sterility certification and pharmacovigilance. Japanese procurement emphasizes traceability and origin certification. Indian and Chinese supply chains face fluctuating domestic raw oil prices and evolving export controls. Regulatory harmonization initiatives in these regions contribute to price movement patterns, particularly with adoption of ICH and PIC/s guidelines.
Outlook for 2026 expects moderate upward price pressure. Main drivers include incremental compliance harmonization in Asia and expanded end-market surveillance in the EU. Global agricultural trends and climate events signal potential increases in base oil prices. Additional regulatory control on packaging materials and additives is anticipated to increase total product cost, especially as countries increase pharmacovigilance and traceability obligations. Data collection draws from industry association updates, public procurement tenders, and raw material futures reports.
Recent years have seen consolidation among oil processors, which tightens sourcing options and impacts long-term contract stability. Regulatory authorities have issued new guidance on allowable extractable profiles for parenteral nutrition components. Some countries have introduced stricter batch release rules for imported medical emulsions, resulting in fluctuating stock levels and shipment scheduling adjustments.
Global harmonization of microbiological criteria and biocompatibility standards are underway, especially in cross-border supply scenarios. Requirements for Data Matrix codes and serializable packaging for injectable medicines continue to expand, boosting production side technical requirements. Several countries have moved to align their release assay expectations with the latest USP and Ph. Eur. monographs, increasing documentation and analytical testing complexity for manufacturers.
Manufacturers have expanded raw material qualification protocols and included alternative sourcing strategies for key ingredients. Enhancements in electronic batch records and in-process analytical controls allow for quicker response to out-of-spec results. Cross-regional technical teams coordinate on regulatory submissions and documentation, aiming to maintain shipment continuity amid evolving import requirements. Where domestic supply shortages appear, coordination with certified oil extractors and full-packaging validations have limited longer-term supply interruptions.
Fat Emulsion Injection demands strict production discipline and validated supply chains due to its direct use in parenteral nutrition. Hospitals and compounding pharmacies rely on finished emulsions for intravenous feeding, especially in patients unable to tolerate enteral intake. Clinical nutrition applications call for high levels of traceability for all input oils, emulsifiers, and water for injection. Veterinary medicine adapts similar emulsions for parenteral feeding in animals, with some latitude in permissible grades depending on national regulations.
Research and development groups may request variant fat emulsions for drug-delivery studies, where physicochemical consistency and the absence of interfering impurities matter more than full pharmacopoeial status. Diagnostic labs and formulation developers often need reference emulsions when simulating intravenous environments or validating analytical methods, so reproducibility, particle size distribution, and endotoxin control are especially scrutinized here.
| Grade | Main Industrial Use | Key Properties | Application Sensitivities |
|---|---|---|---|
| Parenteral Grade | Hospital parenteral nutrition, compounding pharmacies | Foreign particle and microbial profile, pyrogen level, emulsification stability, droplet size limits, strictly pharmaceutical-excipient compliant raw inputs | Requires globally recognized pharmacopeia conformity (such as USP, EP), batch record retention, final filterable sterility validation |
| Veterinary Grade | Animal health, veterinary clinics | Raw input approval, pyrogen check, macronutrient accuracy, particle profile | Labeling and chemical purity depend on regional veterinary practice and legislation; residue controls vary by animal species |
| Research Grade | Formulation development, diagnostics, analytical validation | Reproducibility, sterile filtration, exact droplet size distribution, oxidation resistance | Endotoxin and microbial indicators demand close monitoring, though therapeutic level purity may not be required |
Clinical use for patient nutrition, veterinary supplementation, drug delivery R&D, or lab diagnostics—each scenario triggers distinct quality, stability, and traceability requirements. Feedback from medical staff, protocol standards, and end-point environments guides the technical selection.
Regional rules dictate acceptance criteria; US, EU, or local pharmacopeias stipulate particle size, sterility, and shelf stability. For exports or cross-border procurement, check if local regulators accept the source country's pharmacopeia or set their own limits.
Choose a grade matching the user population: Neonatal, immunocompromised, or at-risk patients require absolute contaminant and pyrogen limits. Veterinary and research users might accept broader bands, but all applications demand documented impurity audits alongside supplier’s internal release standards.
Bulk hospital contracts, research batches, or clinical pilot lots each drive unique order quantities. Parenteral grades in large volume typically cost more due to exhaustive compliance, intense purification, and summarized batch records—these are factored into per-liter cost calculations discussed in procurement negotiations.
Prior to large-scale adoption or registration, major customers perform their own in-house or contract validation: visual tests, particle measurement, and compounding compatibility checks. Manufacturers provide reference samples drawn from standard lots, not special batches, to represent real-world production performance. Final purchase depends on documented lab validation outcomes.
As a direct manufacturer of fat emulsion injections, we operate under certified quality management systems that reflect internationally recognized frameworks for pharmaceutical and parenteral nutrition production. Certification to standards such as ISO 9001 forms the basis for comprehensive operational discipline, while compliance with Good Manufacturing Practice (GMP) standards remains non-negotiable for all parenteral releases. Documentation is maintained through independent audit trails and continuous internal program review. Adherence to these quality management systems impacts all aspects of production, from raw material intake through to batch release, especially as incoming triglyceride sources and emulsification aids may vary between supply regions and application settings.
For clinical nutrition applications, fat emulsion injections must demonstrate compliance with pharmacopeial monographs applicable to their grade—such as those published in the USP, EP, or national pharmacopoeias, depending on the market. Batch-to-batch conformity is established against these stringent standards, with attributes such as particle size distribution, osmolality, pH, and microbial load tested within internally controlled and documented release parameters. Product certification also includes regulatory dossiers and registration support tailored to the requirements of each target country or customer segment.
Full documentation accompanies every batch, including Certificate of Analysis, manufacturing batch records, and traceability reports covering each raw material lot. For customers requiring periodic audits or support in regulatory submissions, we provide in-depth validation summaries, process flow maps, and impurity profiles based on real production runs, not just theoretical targets. Any atypical batch trend or deviation is subjected to a formal investigation, with corrective action documented and customer notification protocols implemented in line with pharmacovigilance expectations for injectable-grade emulsions.
Fat emulsion injection output depends on continuous access to sterile manufacturing environments and validated high-shear mixing capacity. Our facility operates with redundant production trains to prevent single-point failures and to support stable output across seasonal or raw material-related fluctuations. Cooperation modes can address both long-term supply agreements for established protocols and adaptable spot-sourcing arrangements if customers face urgent clinical shortages or regional allocation shifts.
Production scale grows according to demand forecasts, but actual delivery reliability ties back to upstream raw material security, especially for the pharmaceutical-grade lipids and emulsifiers. By qualifying multiple supply sources for each critical component, we avoid dependency risk. Each production run undergoes in-process monitoring for key variables such as particle size homogeneity and sterilization hold time, which directly impact downstream stability and shelf-life for each product grade.
Sample provision to qualified customers follows a defined protocol: documentation of intended use, regulatory context, and quantity required. Each sample shipment carries the standard quality release documentation, with additional analytical data available on request to facilitate customer formulation development, method validation, or tender submission. For formulation screening or compatibility assessment projects, customers may arrange site visits or virtual audits to observe sample production parameters.
Business cooperation can involve annual volume commitments with price adjustment mechanisms pinned to raw material indices, or just-in-time ordering integrated with the customer's forecast system. For clinical trials or specific formulation development, we can schedule dedicated small-batch production. Our technical and commercial teams remain available to coordinate directly with customer quality, procurement, and logistics departments, ensuring open communication around delivery schedules, certification requirements, and regulatory dossier compilation. All modifications in supply terms undergo joint technical and legal review before implementation.
Recent development focuses on the design of emulsifier systems that minimize pro-inflammatory responses, monitoring the clinical impact of triglyceride chain length and the ratio of omega-3 to omega-6 fatty acids. Some production lines emphasize processing technology to control droplet size distribution within grades for neonatal use, parenteral nutrition in septic states, or multi-compartment admixtures. Each formulation pathway requires upstream control over hydrolysis risk, peroxide generation, and leachable metals from raw inputs.
Fat Emulsion Injection continues to find clinical placements outside general nutrition, such as targeted drug delivery, intravenous anesthetic carrier systems, and pediatric metabolic support. These new directions rely on consistent particle sizing, emulsion stability under rapid infusion rates, and low endotoxin profiles. Specialized use may require tailored antioxidant systems and ongoing sterility assurance along with customized lipid profiles depending on hospital nutrition protocols or pharmacological compatibility.
One ongoing challenge is managing oxidative stability through the full shelf life, especially in multi-dose or compounded settings. This includes limiting peroxidation during sterilization and maintaining homogeneity despite temperature cycling or agitation in distribution. Technical progress includes micron-level in-line sizing control, limited-use aseptic process validation, and enzyme-mitigated hydrolysis inhibitors in raw material selection. Regional regulatory differences require separate routines for testing pyrogen generation, heavy metal content, and plant origin traceability of raw oils. Both batch-to-batch consistency and continuous monitoring remain subjects of active technical investment.
Fat Emulsion Injection will see continued demand from medical nutrition and critical care in both mature and emerging healthcare systems. Specification drift from customers is expected towards longer shelf life, compatibility with closed admixture systems, and lower process contaminants. Customization in oil blend profiles is projected to increase as precision nutrition regimens for high-risk populations develop. Market evolution depends on the ability to consistently control key physicochemical properties and respond rapidly to changes in pharmacopeial standards and hospital requirements. Volume is likely to fluctuate based on procurement cycles in public health and availability of alternative nutrition delivery formats.
Expect further integration of advanced on-line monitoring (NIR, particle analytics) during emulsion formation and filling. New grades may prioritize microfiltration strategies, closed-system aseptic transfer, and enhanced packaging to minimize oxygen ingress throughout logistics. Upstream, renewable feedstock implementation and process water recycling remain ongoing targets. Refinement of process control software for predictive maintenance and deviation response will gain importance as run length and batch size increase.
Raw material origin stands as a key concern. Certified sustainable oil sources, traceable supply chains, and eco-friendly antioxidant systems attract both regulatory and market scrutiny. Process improvements emphasize restoration and reuse of solvents in cleaning, reduction of single-use plastics in packaging components, and minimization of waste effluent. Downstream, user preferences for reduced-waste vials, re-cyclable or bio-based components, and transparent lifecycle analyses influence both process revision and product development timelines.
Support teams regularly address raw material compatibility, filter hold-up analysis, admixture stability, and infusion/device integration queries. On-site technical visits verify adherence to internal process protocols and review impact of customer compounding practices on emulsion integrity.
Industrial consultations examine emulsion behavior in fill-finish automation, support dosing pump calibration, and provide heat exposure and agitation resistance studies as needed by the healthcare facility. Specialty cases cover integration with hospital pharmacy compounding and mixed-use admixtures.
Routine follow-up ensures post-delivery technical conformance. Field engineers are available for in-depth troubleshooting with deferred-release lots or when customers encounter variance in droplet sizing, visible phase separation, or filtration backpressure. Customer feedback loops contribute to incremental process refinement, and dedicated technical lines remain available for both urgent troubleshooting and continuous education programs within hospital and distributor networks.
At our facility, fat emulsion injection is produced under regulated conditions using automated batch controls and fully traceable ingredient procurement. Years of process optimization have resulted in stable physical characteristics and tight tolerances for particle size and droplet dispersion. Skilled technicians monitor every stage, from emulsion formation through to sterile filtration, using validated in-process analytics.
Industrial clients draw on fat emulsion injection for intravenous nutrition in hospitals, admixture services at compounding centers, and as a formulation ingredient in specialty clinical nutrition products. Our output supports both high-throughput healthcare providers and custom formulations for research and development pipelines. Manufacturers of ready-to-administer infusion solutions rely on dependable batch scheduling and specification alignment to maintain smooth downstream production.
Chemical analysis, microbiological assessment, and particle size data are documented for each lot. In-line real-time sensors, coupled with frequent sampling, detect deviations before material advances to packaging. Retention samples remain archived and can be accessed for retrospective quality investigations if customers require batch-level data. Our processes align with current Good Manufacturing Practices as audited by regulatory bodies.
Filling lines handle a range of primary packaging sizes suited to bulk resupply or unit-dosed hospital inventory. Production lines operate at scale to support both single-shipment quantities and long-term standing orders. The packaging plant runs label control systems and applies thermal sealing to protect product integrity during transit. Freight can be dispatched in climate-controlled containers with documentation tailored for customs and chain-of-custody verification where regulatory requirements apply.
Comprehensive documentation packages accompany each shipment, including certificates of analysis and full product traceability. Technical staff respond directly to formulation or process-related queries. Clients needing assistance with formulation compatibility or custom blending can consult our chemists and receive prompt, technically grounded guidance based on real production experience and material performance under actual operating conditions.
Commercial buyers gain from predictable lead times anchored by real-world production capacity and fixed contract volumes. Procurement teams benefit from single-source traceability, reducing audit risks and simplifying documentation workflows. Bulk buyers secure continuity of supply through established capacity and proven logistics coordination. Transparent cost structures, stable output, and technical clarity support lasting business relationships and efficient industrial operations without unexpected supply interruptions.
The question about the particle size range gets right to the core of what makes a fat emulsion injection safe for intravenous administration. From our side, particle size distribution emerges at several critical checkpoints throughout production, not just as a test to clear, but as a daily design consideration. There’s a hard, well-understood reason: larger droplets over the accepted range sharply increase embolic risk during infusion. Our years of industrial-scale production back up what published standards have shown—generally, mean droplet diameter falls below 500 nanometers, with the vast majority of droplets even smaller. Every batch, without exception, is analyzed with laser diffraction and light obscuration methods to identify and quantify any oversized droplets above 5 microns. Regulatory guidelines never leave room for miss in this aspect; we continuously tune emulsion parameters (shear mixing, surfactant ratios, homogenization pressure) to maintain a tight particle size spread.
What comes out of our homogenizers isn’t left to chance. We map out particle size in real time during production and throughout shelf-life stability studies. In-process control means sampling from key stages—post-emulsification, pre-sterilization, at filling—so any deviation from the typical range flags corrective action before product release. This is not just about quality, it’s about protecting clinical use and patient outcomes. The confidence we provide to partners and end-users relies on the reliability of this data.
Taken together, particle size and emulsion stability determine product integrity and patient safety. In practical terms, stability means that droplet size does not change significantly during storage, transportation, or administration. Years of experience have shown us that storage temperature and exposure to light play critical roles. That’s why our technical team runs both real-time and accelerated stability studies, constantly watching for cream layer formation, coalescence, or phase separation in the packed bottles. Analytical procedures at intervals extend well beyond regulatory minimums; we measure not only average size but the presence or emergence of large droplets at every timepoint.
Our formulation uses a blend of emulsifiers and antioxidants to support long-term droplet stability. Thorough process validation makes it possible to meet, batch after batch, the tight thresholds set by international pharmacopoeias. Equipment maintenance also matters: we schedule calibration and cleaning of our homogenizers and filling lines to avoid micro-contamination and mechanical inconsistencies that could destabilize the emulsion. Where early warning is needed, our early-warning monitoring catches shifts in droplet distribution, preventing product that even hints at instability from leaving the premises.
Working directly with fat emulsion injections, our technical and R&D teams draw learning from every lot and every market. We keep open channels for feedback from hospitals and clinics, using returned stability or performance data to refine both particle sizing control and shelf-life design. If a shipment shows unusual changes near expiry, we review root causes—not just in formulation, but throughout our logistics process.
This business never stands still. Real-world medical feedback drives us to optimize newer emulsifying agents and advances in process monitoring. We remain committed to full transparency about our in-house data on droplet size and stability, with detailed records available upon request and always ready for scientific review. Secure particle size control and long-term emulsion stability aren’t just box-checking steps—they define how we build confidence across the clinical chain, from our production floor to the patient’s bedside.
Working directly in pharmaceutical production, we encounter daily questions about vial sizes and order requirements for fat emulsion injection. Understanding these details can streamline procurement and ensure healthcare providers maintain a secure supply chain without overstocking or excessive waste.
We manufacture fat emulsion injection in several standard vial sizes to meet the practical needs of hospitals, clinics, and parenteral nutrition providers. The most common packaging volumes are 100 mL, 250 mL, and 500 mL aseptically filled glass vials. By maintaining these sizing standards, our filling lines ensure compatibility with common infusion pumps and dosing protocols. Therapeutic dosing regimens in clinical settings typically fall within these ranges, which has formed the rationale for our current production scale.
Some pharmaceutical buyers express the need for smaller volume vials such as 20 mL or 50 mL units. Our facility can evaluate custom runs for smaller or alternative sizes on a case-by-case basis if justified by clinical application or special storage requirements. Volumes above 500 mL are not routinely produced for stability and sterility reasons.
Our minimum order quantity (MOQ) policy is shaped by GMP compliance, manufacturing line yield, and the shelf life of the fat emulsion injection product. For our standard vial sizes, the MOQ sits at 5,000 vials per batch for each size and specification. We anchor this production scale in order to optimize sterilization cycles and meet regional regulatory batch validation requirements. An MOQ of this magnitude supports targeted risk management by reducing partial-batch losses and keeps per-unit costs competitive for our customers.
Smaller batch requests below 5,000 units can lead to sharply higher unit prices or delays due to cleaning validation and batch integrity standards. Larger orders can be accommodated easily within our filling schedules, as our lines are calibrated for high-volume production. For special vial sizes not part of our standard catalog, the MOQ is determined after a technical review of tools, changeover time, and packaging procurement. These steps preserve product sterility and ensure batch traceability throughout the supply chain.
Frequent shifts in clinical demand, storage space constraints, and strict expiration dating place pressure on procurement managers. By clarifying our vial size range and MOQ policy, we aim to help pharmacies and hospital buyers minimize stockouts while avoiding surplus waste. Batch production at our facility runs on validated, reproducible processes, so clinicians can trust each shipment’s sterility and dosing accuracy.
Experience shows supply challenges often stem from uncertainty in order volume planning or unanticipated consumption spikes. Our solution involves early engagement with technical teams and clear communication on batch size capabilities. In certain critical care scenarios like neonatal or intensive unit feeding, where smaller vials may be essential, our technical staff work with buyers to explore batch customization within our validated process framework. This collaboration helps manage costs, streamline documentation, and maintain uninterrupted patient care.
As direct manufacturers, we see firsthand the value of aligning product formats and minimum order size with the practical realities faced by healthcare professionals. Our ongoing commitment is to keep vial size offerings responsive, MOQ policy transparent, and technical support accessible for clinical teams managing parenteral nutrition. If buyers need detailed technical information or to discuss tailored vial size production, our specialists remain available to guide every step of procurement, from first inquiry to reliable delivery.
As a manufacturer of fat emulsion injections, we prioritize product safety and quality throughout every stage, including transportation and storage. These injectable nutritional emulsions contain sensitive lipid molecules, along with water-soluble components, that are highly susceptible to environmental temperature shifts. A single lapse in temperature exposes the emulsion to physical or chemical destabilization, impacting pharmacological properties and patient safety.
International guidelines—the most widely accepted being those from the World Health Organization and PIC/S—mandate that intravenous fat emulsions stay refrigerated between 2°C and 8°C during distribution and storage. Our production process integrates these criteria as mandatory steps. Each batch undergoes automated temperature monitoring from the time it leaves our filling lines. All outgoing consignments spend minimal time at ambient temperature before entering the pre-cooled logistics zone, maintained by dedicated industrial refrigeration units.
We employ specialized packaging technology tailored to fat emulsion stability demands. These include double-insulated carton designs with phase-change refrigerant packs that resist transient thermal loads in transit. By minimizing the thermal lag and establishing a robust barrier against ambient conditions, we reinforce product integrity even during lengthy customs inspections or air freight.
Our standard shipping containers always integrate calibrated temperature data loggers. These digital loggers store continuous records for every pallet, providing objective evidence of thermal compliance upon arrival. We regularly share these temperature curves with regulatory inspectors and institutional clients. If fluctuations outside the permitted range occur at any stage, our recall policy activates and affected units are withdrawn before reaching end users.
Global distribution of intravenous lipids poses challenges outside the manufacturing plant's control—delays during transit or in customs clearance are frequent risks. We counter this with strong partnerships with pharmaceutical-grade logistics providers, comprehensive training of our shipping staff, and pre-approved contingency plans for unexpected cold chain interruptions. Ultra-low temperature monitoring at transfer points further limits points of failure.
Beyond technology, staff education plays a key role. New logistics team members receive hands-on training in correct cold chain handling of lipids. Their performance is audited and reviewed regularly. We also work closely with partners in destination countries to maintain cold chain continuity right up to the hospital or clinic.
Extensive research shows breakdowns in the cold chain increase the risk of fat droplet aggregation, peroxidation of unsaturated fatty acids, and growth of microbial contaminants. Once a fat emulsion phase-separates, neither shaking nor mechanical mixing restores the original formulation. In intravenous nutrition, a single instance of globule overload can trigger embolic and inflammatory reactions in critically ill patients. Rigorous cold chain compliance is the only safeguard against these risks.
Our commitment as the manufacturer extends beyond regulatory minimums. We proactively invest in the most advanced infrastructure and tracking systems, request feedback from clinical users, and continually improve based on post-market surveillance. Maintaining temperature-stable injectables through the entire route—from factory floor to end-user—remains a daily operational responsibility.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
